biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Ca
2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Phase 1 · small molecule · Refractory B Acute Lymphoblastic Leukemia
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for Refractory B Acute Lymphoblastic Leukemia is a Phase 1 program (small_molecule) at Nanjing Legend Biotech Co. with 1 ClinicalTrials.gov record(s).
Internal code XJTU-BLLCAR-L10D
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Legend Biotech Co.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Refractory B Acute Lymphoblastic Leukemia
- Status
- terminated
- Trials
- 1